https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45112 Wed 26 Oct 2022 13:25:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51839 Wed 20 Sep 2023 16:12:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46370 Wed 16 Nov 2022 08:45:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24776 Helicobacter pylori infection is considered to be causally linked to dyspepsia although only a minority will respond to eradication. In those with EPS, acid suppression therapy is a first line therapy; consider a H₂ blocker even if proton pump inhibitor fails. In PDS, a prokinetic is preferred. Second line therapy includes administration of a tricyclic antidepressant in low doses, or mirtazapine, but not a selective serotonin reuptake inhibitor.]]> Wed 15 Dec 2021 16:08:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11837 Wed 11 Apr 2018 16:30:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16812 Wed 11 Apr 2018 12:55:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30136 Wed 10 Nov 2021 15:14:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31237 Wed 09 Feb 2022 15:56:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47656 Tue 24 Jan 2023 15:26:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25796 Tue 11 Feb 2020 09:19:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38580 Tue 09 Nov 2021 15:45:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38811 Tue 08 Feb 2022 14:30:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37731 Thu 27 Jan 2022 15:57:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53983 Thu 25 Jan 2024 13:04:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39902 Thu 14 Jul 2022 12:11:05 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50280 Thu 13 Jul 2023 10:29:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48867 Thu 13 Apr 2023 10:07:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36110 Thu 06 Feb 2020 14:11:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36107 Thu 06 Feb 2020 13:57:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30164 Thu 04 Nov 2021 10:38:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7452 Sat 24 Mar 2018 08:38:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14184 1% predicted of 76%, and 69% were taking inhaled corticosteroids. Thirteen healthy controls without asthma were also assessed. Inflammatory cell counts were performed, and RNA was extracted from selected sputum. Transcriptional profiles were generated (Illumina Humanref-8 V2) and analyzed by using GeneSpring GX11. Results: Unsupervised hierarchical clustering of gene expression profiles in asthma revealed 3 distinct groups. The first transcriptional phenotype (n = 21) had lower FEV₁% predicted and higher asthma control questionnaire scores, exhaled nitric oxide, and sputum eosinophils. The second transcriptional phenotype (n = 14) had lower FEV₁% predicted and forced vital capacity % predicted and higher sputum neutrophils compared with a third transcriptional phenotype (n = 24) that had higher sputum macrophages and resembled healthy controls. Differentially expressed genes between transcriptional asthma phenotypes were related to inflammatory and immune responses. Genes in the IL-1 and TNF-α/nuclear factor-κB pathways were overexpressed and correlated with clinical parameters and neutrophilic airway inflammation. Conclusion: Gene expression profiling provides a novel means to investigate the molecular mechanisms and classifications of asthma phenotypes. There are 3 distinct transcriptional phenotypes of asthma that relate to both clinical and inflammatory parameters.]]> Sat 24 Mar 2018 08:21:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12382 Sat 24 Mar 2018 08:18:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12433 Sat 24 Mar 2018 08:15:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12329 Sat 24 Mar 2018 08:11:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20832 12% change in FEV₁; AUC, 91.5%). ICS treatment reduced the expression of CLC, CPA3, and DNASE1L3 in patients with eosinophilic asthma. Conclusions: A sputum gene expression signature of 6 biomarkers reproducibly and significantly discriminates inflammatory phenotypes of asthma and predicts ICS treatment response. This signature has the potential to become a useful diagnostic tool to assist in the clinical diagnosis and management of asthma.]]> Sat 24 Mar 2018 08:05:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17293 Sat 24 Mar 2018 08:01:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19930 Sat 24 Mar 2018 07:58:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:6617 Sat 24 Mar 2018 07:46:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27132 Brachyspira in colonic biopsies, is uncommon and considered of doubtful significance. We aimed to determine the prevalence of CS in the general population, identify subtle colon pathologies, and evaluate a link with symptoms of IBS. Colonoscopy was performed in 745 subjects (aged 19-70 years, mean age 51 years, 43% male) with biopsies (ileum and 4 colonic sites) from a random population sample, Stockholm, Sweden, who completed a validated questionnaire of gastrointestinal symptoms; IBS was identified by Rome III criteria. CS was identified by histology and immunohistochemistry. In a general population, 17 individuals (2.28%; 95% confidence interval, 1.2%-3.5%) were diagnosed as having CS by histology; 6 (35%) had IBS. CS was always present in the sigmoid colon, but only 14 rectal biopsies. Eosinophils were increased in colon biopsies in CS cases versus controls, in the transverse (P =.02), sigmoid colon (P =.001), and rectum (P =.0005) with subepithelial eosinophil clusters (P =.053). Lymphoid follicles (at any site) were present in 13 CS (P =.0003). There was a 3-fold increased risk of IBS in CS (odds ratio, 3.59; 95% confidence interval, 1.27-10.11; P =.015). Polyps and diverticular disease were similar in CS cases and controls. The prevalence of CS in a general population is 2% and associated with nonconstipating IBS. Colonic eosinophilia with lymphoid follicles may signify the presence of CS.]]> Sat 24 Mar 2018 07:33:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4795 Sat 24 Mar 2018 07:20:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22162 Immunity, Griseri et al. (2015) identify a new GM-CSF-dependent role for eosinophils in the pathogenesis of IL-23-Th17 cell-induced colitis.]]> Sat 24 Mar 2018 07:14:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22734 Sat 24 Mar 2018 07:12:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38984 9/L and FENO ≤29 ppb. Exacerbations requiring medical intervention were recorded. Results: Among 220 non-smokers (n = 109 control, n = 111 FENO), 1006 treatment decisions were made, with significant group differences after the first and second algorithm applications. 53% of women had NEA. Treatment was better targeted to phenotype in the FENO group: ICS use increased in eosinophilic asthma (EA, 48–86%), while ICS/LABA increased in NEA (11–30%). Fewer women in the FENO group had exacerbations during pregnancy in NEA only (18.9% FENO vs 44% control, P = 0.006). Conclusion: The FENO algorithm was more effective in treating NEA, resulting in reduced exacerbations, compared to a symptom control algorithm. This was not the result of ICS overtreatment, since the benefits occurred at a lower median daily ICS dose. Two applications of the FENO-guided algorithm, one month apart, were sufficient to achieve beneficial effects in terms of asthma exacerbations, among pregnant women with asthma.]]> Mon 29 Jan 2024 17:52:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53126 Fri 17 Nov 2023 12:21:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40046 Fri 15 Jul 2022 10:05:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47355 Fri 13 Jan 2023 13:26:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49401 Fri 12 May 2023 14:41:29 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53577 Fri 08 Dec 2023 15:38:57 AEDT ]]>